The IGF axis and hepatocarcinogenesis - PubMed (original) (raw)

Review

The IGF axis and hepatocarcinogenesis

J G Scharf et al. Mol Pathol. 2001 Jun.

Abstract

Deregulation of the insulin-like growth factor (IGF) axis, including the autocrine production of IGFs, IGF binding proteins (IGFBPs), IGFBP proteases, and the expression of the IGF receptors, has been identified in the development of hepatocellular carcinoma (HCC). Characteristic alterations detected in HCC and hepatoma cell lines comprise the increased expression of IGF-II and the IGF-I receptor (IGF-IR), which have emerged as crucial events in malignant transformation and the growth of tumours. Alterations of IGFBP production and the proteolytic degradation of IGFBPs resulting in an excess of bioactive IGFs, as well as the defective function of the IGF degrading IGF-II/mannose 6-phosphate receptor (IGF-II/M6PR), may further potentiate the mitogenic effects of IGFs in the development of HCC.

PubMed Disclaimer

Figures

Figure 1

Expression of insulin-like growth factor I (IGF-I), IGF-II, IGF binding protein 1 (IGFBP-1), IGFBP-4, the IGF-I receptor (IGF-IR), and IGF-II/M6PR (mannose 6-phosphate receptor) in rat liver after low number pancreatic islet transplantation into the livers of streptozotocin induced diabetic rats. Schematic illustration demonstrating representative results from immunohistochemical analysis and in situ hybridisation of antisense mRNA to normal liver (normal; N), to glycogen storing foci (GSF; circular area within the square), and hepatocellular carcinoma (HCC) developing after pancreatic islet transplantation. The intensity of gene expression is directly proportional to the darkness of the section. The circular area (hatched) within the circle is a schematic representation of a transplanted pancreatic islet within the GSF.

Similar articles

• The role of the IGF axis in hepatocarcinogenesis.
  Scharf JG, Braulke T. Scharf JG, et al. Horm Metab Res. 2003 Nov-Dec;35(11-12):685-93. doi: 10.1055/s-2004-814151. Horm Metab Res. 2003. PMID: 14710347 Review.
• Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC).
  Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, Hartmann H. Scharf JG, et al. Carcinogenesis. 1998 Dec;19(12):2121-8. doi: 10.1093/carcin/19.12.2121. Carcinogenesis. 1998. PMID: 9886566
• An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
  Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. Alexia C, et al. Biochem Pharmacol. 2004 Sep 15;68(6):1003-15. doi: 10.1016/j.bcp.2004.05.029. Biochem Pharmacol. 2004. PMID: 15313394 Review.

Cited by

• Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.
  Huang Y, Huang L, Zhu J, Wu Y, Shi J, Dai K. Huang Y, et al. Clin Exp Immunol. 2022 May 13;208(1):47-59. doi: 10.1093/cei/uxac011. Clin Exp Immunol. 2022. PMID: 35560184 Free PMC article.
• The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
  Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. Ngo MT, et al. Int J Mol Sci. 2021 Feb 16;22(4):1931. doi: 10.3390/ijms22041931. Int J Mol Sci. 2021. PMID: 33669204 Free PMC article. Review.
• TMS-Induced Controlled BBB Opening: Preclinical Characterization and Implications for Treatment of Brain Cancer.
  Vazana U, Schori L, Monsonego U, Swissa E, Pell GS, Roth Y, Brodt P, Friedman A, Prager O. Vazana U, et al. Pharmaceutics. 2020 Oct 5;12(10):946. doi: 10.3390/pharmaceutics12100946. Pharmaceutics. 2020. PMID: 33027965 Free PMC article.
• Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
  Simon TG, Chan AT. Simon TG, et al. Clin Liver Dis. 2020 Nov;24(4):549-576. doi: 10.1016/j.cld.2020.06.002. Epub 2020 Aug 25. Clin Liver Dis. 2020. PMID: 33012445 Free PMC article. Review.
• Pharmacological Benefits and Risk of Using Hormones in Organ Perfusion and Preservation Solutions in the Aspect of Minimizing Hepatic Ischemia-Reperfusion Injury during Storage.
  Ostróżka-Cieślik A, Dolińska B. Ostróżka-Cieślik A, et al. Biomed Res Int. 2019 Nov 11;2019:6467134. doi: 10.1155/2019/6467134. eCollection 2019. Biomed Res Int. 2019. PMID: 31828112 Free PMC article. Review.

References

1. 1. LeRoith D, Baserga R, Helman L, et al. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54–9. - PubMed
2. 1. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–44. - PubMed
3. 1. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;2:143–63. - PubMed
4. 1. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1–6. - PubMed
5. 1. Braulke T. Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 1999;31:242–6. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal